Hyperfine is still early in its story as the first FDA-cleared AI-powered portable brain MRI, built for point-of-care use where most of the world lacks timely MRI access. It just passed 1,000 clinical scans and partners with Nvidia on AI imaging. Sales rose 83% last quarter at 51% gross margin, revenue has grown four quarters in a row, and cash runway extends into 2028, though it is unprofitable. Light institutional coverage is a plus; the stock just broke out, with $2.00 a big hurdle. x.com 

Hyperfine's portable MRIs are a great concept with long-term potential, and European launches are coming. Q1 sales rose 83% year over year, gross margin holds steady around 50% and cash burn fell slightly, while a current ratio above 4 and quick ratio of 3.5 give a cushion. The big catalyst would be a massive sales runway or profitability, which still looks far off. The chart shows a bull flag. x.com